Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 16, Number 7—July 2010

Synopsis

Oseltamivir Resistance in Adult Oncology and Hematology Patients Infected with Pandemic (H1N1) 2009 Virus, Australia

Adrian R. TramontanaComments to Author , Biju George, Aeron C. Hurt, Joseph S. Doyle, Katherine Langan, Alistair B. Reid, Janet M. Harper, Karin Thursky, Leon J. Worth, Dominic E Dwyer, C. Orla Morrissey, Paul D.R. Johnson, Kirsty L. Buising, Simon James Harrison, John F. Seymour, Patricia E. Ferguson, Bin Wang, Justin T. Denholm, Allen C. Cheng, and Monica Slavin
Author affiliations: Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia (A.R. Tramontana, K. Thursky, L.J. Worth, S.J. Harrison, J.F. Seymour, M. Slavin); Western Hospital, Footscray, Victoria, Australia (A.R. Tramontana); Westmead Hospital, Sydney, New South Wales, Australia (B. George, D.E. Dwyer, B. Wang), World Health Organization Collaborating Centre for Reference and Research on Influenza, North Melbourne, Victoria, Australia (A.C. Hurt); The Alfred Hospital, Prahran, Victoria, Australia (J.S. Doyle, C.O. Morrissey); Austin Health, Heidelberg, Victoria, Australia (K. Langan, P.D.R. Johnson); St. Vincent’s Hospital, Melbourne, Victoria, Australia (A.B. Reid, K.L. Buising); Royal Melbourne Hospital, Melbourne (J.M. Harper, J.T. Denholm, M. Slavin); Centre for Infectious Diseases and Microbiology, Sydney (P.E. Ferguson); Monash University, Prahran (A.C. Cheng)

Main Article

Table 2

Characteristics of 4 patients infected with oseltamivir-resistant pandemic influenza A (H1N1) virus isolates, Australia*†

Characteristic Patient no.
1 5 12 20
Within 100 days of HSCT‡ No Yes No
Time to development of resistance, d 22 11§ 8 4
Time of last positive NAT result, d 28 16 8 4
Change to zanamivir Yes No No No
Time to zanamivir, d 36
Died Yes Yes No No
LOS, d 39 66 21 9

*HSCT, hematopoietic stem cell transplant; NAT, nucleic acid test; LOS, length of stay.
†Oseltamivir resistance was influenza virus with H275Y mutation.
‡Time from commencement of oseltamivir.
§Detected in bronchoalveolar lavage specimen with negative NAT on nasopharyngeal swab 3 d before first and 10 d after last bronchoscopy. This patient received oseltamivir for 5 d.

Main Article

Top of Page

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO